Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Transcenta's Osemitamab (TST001) Targeting Claudin18.2 Granted Orphan Drug Designation for Treatment of Pancreatic Cancer 2023-03-29 14:00
Transcenta Announces First Patient Dosed in the U.S. Study of Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors 2023-03-23 08:00
Transcenta to Present Two Preclinical Studies at AACR 2023 2023-03-23 08:00
Transcenta Holding Limited (6628.HK) to Hold 2022 Annual Results Release Conference Call 2023-03-20 21:12
Results of CLDN18.2-targeting Immuno-PET Probe for Non-invasive Imaging in Gastrointestinal Tumors Published 2023-03-03 14:56
Transcenta to Present "Trial in Progress" at ASCO-GI 2023 for TST001 (Osemitamab) Combination with Nivolumab, with or without Chemotherapy in Advanced G/GEJ Cancer 2023-01-18 08:00
Transcenta Received IND Clearance from NMPA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors 2023-01-04 08:00
Transcenta Presented Two Scientific Posters at SITC 2022 Annual Meeting 2022-11-11 08:00
Transcenta to Hold 3 Exchange Sessions on Post-SITC Business Update Call & TST003 data release and pipeline development progress update 2022-11-09 21:09
Transcenta to Participate in Four Upcoming Conferences 2022-10-24 21:00
Transcenta To Present First-In-Class TST003 Antibody Program at the 10th TEMTIA Meeting 2022-10-24 16:08
Transcenta to Present Two Scientific Posters at SITC 2022 Annual Meeting 2022-10-14 08:00
Transcenta Received IND Clearance from FDA for Its Best-In-Class MASP2 Targeting Antibody TST004 for the Treatment of IgA Nephropathy 2022-10-05 08:00
Transcenta Received IND Clearance from FDA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors 2022-09-14 14:18
Transcenta Releases Encouraging Interim Safety and Efficacy Data of the TST001 (Osemitamab) and Chemotherapy Combination Expansion Cohort for First Line Claudin18.2 Positive Gastric Cancer at ESMO Congress 2022 2022-09-13 08:00
Transcenta Announces the Appointment of Dr. Caroline Germa as Executive Vice President, Global Medicine Development and Chief Medical Officer 2022-08-08 08:00
Transcenta to Present Interim Safety and Efficacy Data of the TST001 and Chemotherapy Combination Expansion Cohort for Claudin18.2 Positive First Line Gastric Cancer at ESMO Congress 2022 2022-07-28 08:00
Transcenta was Selected to Present the Preclinical Data of TST004 at the 2022 ISN Frontiers Meetings of Complement Related Kidney Diseases 2022-06-28 08:00
Transcenta Releases Phase I Clinical Data of TST001 in Combination with CAPOX as the First Line Treatment of Advanced and Metastatic G/GEJ Cancer at ASCO 2022 2022-06-02 08:08
Nature Cancer Publishes the Collaborative Study Results by Transcenta and Shanghai Jiao Tong University Scientists 2022-05-31 08:08
1 2 3